VCNX Profile
Vaccinex, Inc. is a clinical-stage biotechnology company specializing in developing novel therapies for cancer and neurodegenerative diseases through targeted inhibition of semaphorin 4D (SEMA4D). SEMA4D is a protein involved in various disease processes, including tumor immune evasion and chronic neuroinflammation. The company's primary therapeutic candidate, pepinemab, is designed to block SEMA4D, thereby enhancing immune system access to tumors and mitigating inflammation in the brain associated with chronic diseases.
Pepinemab is currently undergoing clinical evaluation in several key studies. In oncology, it is being tested in a Phase 1b/2 trial for recurrent or metastatic head and neck cancer, aiming to assess its efficacy in overcoming tumor-induced immune resistance. In neurology, pepinemab is being investigated in a Phase 1/2a trial for Alzheimer's Disease, focusing on its potential to alleviate neuroinflammation and improve cognitive function. Additionally, Vaccinex is exploring the drug's potential in Phase 3 development for Huntington's disease, a progressive neurodegenerative condition.
Beyond its lead candidate, Vaccinex has developed a proprietary drug discovery platform known as ActivMAb. This platform is pivotal for the company’s strategy to identify and develop antibodies targeting multi-pass membrane receptors, which are crucial in many diseases. Through ActivMAb, Vaccinex collaborates with strategic partners to enhance the development of innovative therapies, leveraging its platform's unique capabilities to address complex biological targets.
Founded in 2001 and headquartered in Rochester, New York, Vaccinex has established itself as a key player in the biotechnology sector. The company continues to advance its research and clinical programs, aiming to deliver transformative therapies for patients with unmet medical needs. Its ongoing efforts in drug development and strategic collaborations underscore its commitment to innovation and addressing critical health challenges.
|
